NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
(1S,2R)-2-amino-1-phenylpropan-1-ol
|
|
|
IUPAC Traditional name
|
|
Brand Name
|
Acutrim
|
Ami-Tex
|
Codimal
|
Conex
|
Contuss
|
Despec
|
Dexatrim
|
Dura-Vent
|
Entex
|
Gentab
|
Guaipax
|
Myminic
|
Naldecon
|
Nolex
|
Partuss
|
Phenoxine
|
Phenyldrine
|
Phenylfenesin
|
Propagest
|
Rhindecon
|
Rhymed
|
Snaplets
|
Triaminic
|
ULR
|
Vanex
|
|
|
Synonyms
|
(1S,2R)-2-Amino-1-phenyl-1-propanol
|
erythro-α-(1-aminoethyl)benzyl alcohol
|
D-(+)-Norephedrine
|
Phenylpropanolamine
|
(1S,2R)-(+)-Norephedrine
|
(+-)-Phenylpropanolamine
|
(+/-)-Norephedrin
|
PPA
|
Phenylpropanolamine
|
D-(+)-Norephedrine
|
(1S,2R)-2-氨基-1-苯基-1-丙醇
|
D-(+)-去甲麻黄素
|
苯丙醇胺
|
赤型-α-(1-氨基乙基)苄醇
|
(1S,2R)-(+)-去甲麻黄素
|
D-(+)-去甲麻黄素
|
|
|
CAS Number
|
|
MDL Number
|
|
Beilstein Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
Acid pKa
|
13.896164
|
H Acceptors
|
2
|
H Donor
|
2
|
LogD (pH = 5.5)
|
-2.0889428
|
LogD (pH = 7.4)
|
-1.0537072
|
Log P
|
0.8852543
|
Molar Refractivity
|
44.9127 cm3
|
Polarizability
|
18.00672 Å3
|
Polar Surface Area
|
46.25 Å2
|
Rotatable Bonds
|
2
|
Lipinski's Rule of Five
|
true
|
Log P
|
0.57
|
LOG S
|
-0.87
|
Solubility (Water)
|
2.06e+01 g/l
|
DETAILS
DETAILS
DrugBank
Sigma Aldrich
DrugBank -
DB00397
|
Item |
Information |
Drug Groups
|
approved; withdrawn |
Description
|
Phenylpropanolamine has been withdrawn in Canada. In November 2000, the Food and Drug Administration (FDA) issued a public health advisory against the use of the drug. |
Indication |
For the treatment of nasal congestion, control of urinary incontinence, priapism and obesity. |
Pharmacology |
Phenylpropanolamine (PPA), a sympathomimetic agent structurally similar to pseudoephedrine, is used to treat nasal congestion. Phenylpropanolamine is found in appetite suppressant formulations and with guaifenesinin in cough-cold formulations. In 2000, the FDA requested that all drug companies discontinue marketing products containing phenylpropanolamine, due to an increased risk of hemorrhagic stroke in women who used phenylpropanolamine. |
Toxicity |
May induce ventricular extrasystoles and short paroxysms of ventricular tachycardia, a sensation of fullness in the head and tingling of the extremities; LD50=1490mg/kg (orally in rat) |
Affected Organisms |
• |
Humans and other mammals |
|
Biotransformation |
Hepatic |
Absorption |
Reduced bioavailability (about 38%) from gastrointestinal tract because of first pass metabolism by monoamine oxidase in the stomach and liver. |
Half Life |
2.1 to 3.4 hours. |
External Links |
|
|
PATENTS
PATENTS
PubChem Patent
Google Patent